Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kissei Pharmaceutical Co., Ltd. (4547.T)
Matsumoto, JP
Kissei Pharmaceutical Co., Ltd. specializes in the discovery, development, production, and commercialization of pharmaceutical products, with a primary focus on the Japanese market. Its marketed pharmaceuticals encompass Urief and Urief OD tablets, designed to alleviate dysuria. For type 2 diabetes, it provides Glufast, Glubes, and Marizev tablets. Treating renal anemia, the company offers Darbepoetin Alfa BS and Epoetin Alfa BS injections. Beova tablets are available for managing overactive bladder, while hyperphosphatemia patients can utilize P-TOL chewable tablets. Furthermore, Minirin Melt OD tablets address a range of conditions including nocturia caused by nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis stemming from reduced urine osmolality. Kissei maintains a robust product pipeline, featuring KPS-0373, which has successfully completed Phase III clinical trials for spinocerebellar ataxia, and CCX168, also a completed Phase III candidate, targeting microscopic polyangiitis and granulomatosis with polyangiitis. Currently undergoing Phase III trials are AJM300 for ulcerative colitis, R788 for chronic idiopathic thrombocytopenic purpura, and MR13A9 to alleviate uremic pruritus in dialysis patients. Other investigational compounds include KLH-2109 for endometriosis and uterine fibroids, KDT-3594 for Parkinson's disease, Silodosin addressing dysuria linked to benign prostatic hyperplasia, Mitiglinide for type 2 diabetes mellitus, and Bedoradrine for the management of acute asthma exacerbations. Beyond its pharmaceutical endeavors, Kissei also manufactures and markets specialized nutritional products, such as protein-controlled and energy-supplying foods, and engages in the procurement and sale of associated raw materials. Furthermore, the company extends its operations to include system development, information processing, construction services, equipment and facility oversight, alongside information collection and development assistance. Founded in 1946 as Kissei Yakuhin Kogyo Co., Ltd., the company adopted its present name, Kissei Pharmaceutical Co., Ltd., in October 1964. Its corporate headquarters are situated in Matsumoto, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.91% | +0.81% | -6.91% | -5.51% | +5.93% | -5.20% | +8.70% | +49.62% | +109.23% | +82.14% | +93.58% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 2 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+10.3% ★ Q1'26: +9.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+20.9% ★ Q1'26: -8.4% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-7.6% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-3.0% Q1'26: +3.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-1.4% Q1'26: +1.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-4.7% ★ Q1'26: -3.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.73× ★ Q1'26: 0.16× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 6 Rev. Ana. 6 EPS Ana. |
Mar 2027 3 Rev. Ana. 3 EPS Ana. |
Mar 2028 6 Rev. Ana. 6 EPS Ana. |
Mar 2029 5 Rev. Ana. 5 EPS Ana. |
Mar 2030 2 Rev. Ana. 1 EPS Ana. |
Mar 2031 1 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
70.11B
est: 69.00B (+1.6%)
|
71.29B
est: 72.00B (-1.0%)
|
71.71B
est: 70.90B (+1.1%)
|
74.01B
est: 74.90B (-1.2%)
|
72.30B
est: 73.33B (-1.4%)
|
63.23B
est: 61.40B (+3.0%)
|
69.04B
est: 67.60B (+2.1%)
|
65.38B
est: 65.45B (-0.1%)
|
67.49B
est: 68.43B (-1.4%)
|
75.58B
est: 77.43B (-2.4%)
|
88.33B
est: 86.66B (+1.9%)
|
96.46B
95.68B – 97.45B
+11.3% YoY
|
98.33B
97.05B – 99.18B
+1.9% YoY
|
104.29B
97.83B – 114.58B
+6.1% YoY
|
109.93B
108.83B – 111.04B
+5.4% YoY
|
116.78B
112.31B – 123.22B
+6.2% YoY
|
121.49B
116.84B – 128.19B
+4.0% YoY
|
| EBITDA |
12.70B
est: 16.63B (-23.6%)
|
13.51B
est: 17.35B (-22.1%)
|
12.51B
est: 17.09B (-26.8%)
|
14.21B
est: 18.05B (-21.3%)
|
9.75B
est: 17.67B (-44.8%)
|
7.21B
est: 14.80B (-51.2%)
|
10.65B
est: 16.29B (-34.6%)
|
20.26B
est: 15.77B (+28.4%)
|
17.81B
est: 16.49B (+8.0%)
|
18.72B
est: 16.54B (+13.2%)
|
20.25B
est: 18.51B (+9.4%)
|
20.61B
20.44B – 20.82B
+11.3% YoY
|
21.01B
20.73B – 21.19B
+1.9% YoY
|
22.28B
20.90B – 24.48B
+6.1% YoY
|
23.49B
23.25B – 23.72B
+5.4% YoY
|
24.95B
23.99B – 26.32B
+6.2% YoY
|
25.96B
24.96B – 27.39B
+4.0% YoY
|
| EBIT |
10.50B
est: 12.87B (-18.4%)
|
11.17B
est: 13.43B (-16.9%)
|
10.14B
est: 13.23B (-23.3%)
|
11.72B
est: 13.97B (-16.1%)
|
7.14B
est: 13.68B (-47.8%)
|
4.65B
est: 11.46B (-59.4%)
|
7.50B
est: 12.61B (-40.5%)
|
16.53B
est: 12.21B (+35.4%)
|
13.70B
est: 12.77B (+7.3%)
|
14.47B
est: 12.30B (+17.6%)
|
15.63B
est: 13.76B (+13.6%)
|
15.32B
15.19B – 15.48B
+11.3% YoY
|
15.62B
15.41B – 15.75B
+1.9% YoY
|
16.56B
15.54B – 18.20B
+6.1% YoY
|
17.46B
17.28B – 17.63B
+5.4% YoY
|
18.55B
17.84B – 19.57B
+6.2% YoY
|
19.29B
18.56B – 20.36B
+4.0% YoY
|
| Net Income |
7.17B
est: 7.35B (-2.5%)
|
8.17B
est: 6.91B (+18.2%)
|
7.73B
est: 7.09B (+9.0%)
|
9.05B
est: 7.26B (+24.5%)
|
5.48B
est: 5.57B (-1.5%)
|
2.82B
est: 3.83B (-26.4%)
|
5.29B
est: 4.25B (+24.4%)
|
12.92B
est: 3.41B (+278.6%)
|
10.53B
est: 9.93B (+6.0%)
|
11.16B
est: 11.25B (-0.8%)
|
11.96B
est: 10.70B (+11.7%)
|
13.11B
12.88B – 13.17B
+22.5% YoY
|
12.29B
10.30B – 13.52B
-6.2% YoY
|
12.02B
9.55B – 16.59B
-2.2% YoY
|
12.33B
10.61B – 18.07B
+2.6% YoY
|
16.39B
15.57B – 17.56B
+32.9% YoY
|
20.51B
19.49B – 21.98B
+25.2% YoY
|
| SGA |
22.42B
est: 22.05B (+1.6%)
|
22.53B
est: 23.01B (-2.1%)
|
23.38B
est: 22.66B (+3.2%)
|
23.08B
est: 23.94B (-3.6%)
|
22.58B
est: 23.44B (-3.7%)
|
21.13B
est: 19.62B (+7.7%)
|
19.61B
est: 21.61B (-9.3%)
|
19.92B
est: 20.92B (-4.8%)
|
20.30B
est: 21.87B (-7.2%)
|
20.79B
est: 25.28B (-17.7%)
|
22.18B
est: 28.29B (-21.6%)
|
31.49B
31.23B – 31.81B
+11.3% YoY
|
32.10B
31.68B – 32.38B
+1.9% YoY
|
34.04B
31.93B – 37.40B
+6.1% YoY
|
35.89B
35.53B – 36.25B
+5.4% YoY
|
38.12B
36.66B – 40.22B
+6.2% YoY
|
39.66B
38.14B – 41.84B
+4.0% YoY
|
| EPS |
142.13
est: 168.55 (-15.7%)
|
166.88
est: 158.41 (+5.3%)
|
158.73
est: 162.49 (-2.3%)
|
188.24
est: 166.49 (+13.1%)
|
117.33
est: 127.60 (-8.0%)
|
60.30
est: 87.80 (-31.3%)
|
113.25
est: 97.41 (+16.3%)
|
280.19
est: 78.24 (+258.1%)
|
228.30
est: 227.69 (+0.3%)
|
246.58
est: 267.85 (-7.9%)
|
274.20
est: 254.76 (+7.6%)
|
312.84
309.94 – 316.92
+22.8% YoY
|
281.41
247.91 – 325.26
-10.0% YoY
|
312.15
229.83 – 399.27
+10.9% YoY
|
349.99
255.40 – 434.82
+12.1% YoY
|
394.29
374.66 – 422.55
+12.7% YoY
|
493.46
468.89 – 528.82
+25.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-01 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares International Developed Small Cap Value Factor ETF ISVL | 0.10% | 314.7K | 0.31% |
| 2 | State Street SPDR S&P International Small Cap ETF GWX | 0.08% | 673.4K | 0.40% |
| 3 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.06% | 321.0K | 0.58% |
| 4 | iShares MSCI Japan Small-Cap ETF SCJ | 0.05% | 122.2K | 0.50% |
| 5 | Schwab International Small-Cap Equity ETF SCHC | 0.03% | 1.67M | 0.06% |
| 6 | Avantis International Small Cap Equity ETF AVDS | 0.03% | 86.3K | 0.30% |
| 7 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.02% | 2.80M | 0.06% |
| 8 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.02% | 44.4K | 0.83% |
| 9 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.02% | 2.67M | 0.40% |
| 10 | Vanguard International Dividend Appreciation ETF VIGI | 0.02% | 1.58M | 0.07% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hiroshi Noake | GM of Pharmaceutical Sales Headquarters & Director | — | — |
| Keiji Fukushima | Executive Vice President & Director | — | male |
| Keiji Miyazawa | GM of Research Division & Director | — | — |
| Mutsuo Kanzawa | Chairman & Chief Executive Officer | — | male |
| Takahide Kitahara | GM of Financial Management Department, MD & Director | — | male |
| Tetsu Takayama | Executive MD, CHRO & Director | — | male |
| Yasuo Takehana | President, Chief Operating Officer & Director | — | male |
| Yoshio Furihata | Senior Advisor & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4547.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
